Samsung Epis Holdings: Q1 2026 Swings to Profit, Biosimilar and Novel Drug Pipeline Advances
Consolidated Q1 2026 revenue: KRW 453.9B, operating profit KRW 90.5B (vs prior KRW 251.7B and -63.6B loss), turning to profit.
Net income KRW 99.5B (vs prior KRW 85.3B after restatement).
Debt ratio 34.1%, net debt ratio 10.5% – very healthy financial structure.
Revenue from key partners (Biogen, Organon, Sandoz) 73.9% of total sales (down from 81.1%, showing diversification).
11 biosimilars commercialized. SB27 (Keytruda biosimilar) in Phase 3.
Follow-on biosimilars SB33~SB38 in process development or completed.
Novel drug pipeline: ADC (SBE303 Nectin-4 ADC Phase 1; SBE313 EGFR-HER3 ADC preclinical) and long-acting obesity drug (Semaglutide LAI preclinical) under co-development.
Standalone (holding company) has no revenue – dependent on subsidiaries.
Contingent liabilities exist (e.g., European patent dispute on adalimumab formulation), but management deems not material.
Correction of prior-year tax error increased net income by KRW 116.7B (one-time).